<i>ERCC6L</i>, a DNA helicase, is involved in cell proliferation and associated with survival and progress in breast and kidney cancers

Pu, Shao-Yan; Yu, Qin; Wu, Huan; Jiang, Jianjun; Chen, Xiao-Qiong; He, Yonghan; Kong, Qing‐Peng

doi:10.18632/oncotarget.14998

Cited by 35 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, data from 106 paired breast cancer samples at different pathological stages from TCGA were analyzed, and it was demonstrated that ERCC6L was highly expressed in 91.51% (97/106), unchanged in 7.54% (8/106) and decreased in 0.94% (1/106) of breast cancer samples compared with matched controls. This result was in agreement with that reported by Pu et al (16). Previous studies also suggested that ERCC6L is highly expressed in several types of tumor, including bladder, kidney, oral and gastric cancers (17)(18)(19)(20).…”

Section: Discussionsupporting

confidence: 93%

“…DNA helicases are important components of DNA replication, recombination and repair in all eukaryotes and bacteria; in response to aberrant ERCC6L functioning, DNA damage and genetic instability are induced, which in turn may enhance cancer development (19). Pu et al (16) reported that ERCC6L knockdown induces G0/G1 cell cycle arrest and inhibits cell proliferation, but does not increase apoptosis of MCF-7 breast cancer cells. However, in the present study, it was demonstrated that downregulation of ERCC6L in breast cancer cells using a shRNA-containing lentivirus, caused cell growth inhibition, apoptosis and cell phase distribution.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

et al. 2018

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease with a high degree of diversity with regards to tumor histological stage and molecular subtypes. These heterogeneous characteristics determine the risk of disease progression and therapeutic resistance. Understanding tumor heterogeneity is of primary concern to identify and develop novel and specific potential targets for diagnosis and therapy. The present study analyzed 106 paired breast cancer tissues from The Cancer Genome Atlas and demonstrated that excision repair cross‑complementation group 6 like (ERCC6L), a newly discovered DNA helicase, was overexpressed in 91.51% (97/106), unchanged in 7.54% (8/106) and decreased in 0.94% (1/106) of breast cancer samples. A short hairpin RNA ERCC6L lentivirus was constructed to investigate the role of ERCC6LR in cancer. First, a Celigo Image Cytometry system was used to detect MDA‑MB‑231 cell growth number following transfection with shERCC6L‑lentivirus or NC‑lentivirus and it was identified that the growth number of fluorescent MDA‑MB‑231 cells post‑transduction with shERCC6L‑lentivirus was decreased compared with the cells transduced with NC‑lentivirus. Then, the effect of knockdown of ERCC6L expression on the cell cycle distribution and apoptosis was to analyzed using fluorescence‑activated cell sorting (FACS). The FACS data demonstrated that knockdown of ERCC6L expression levels in MDA‑MB‑231 cells significantly increased S phase population but decreased the G1 and G2/M phase populations compared with the NC group. The apoptosis rate of MDA‑MB‑231 cells post‑transduction with shERCC6L‑lentivirus for 5 days was increased to 12.16±0.146% compared with the negative control rate (4.86±0.204%). These functional studies demonstrated that knockdown of ERCC6L expression levels in MDA‑MB‑231 cells significantly inhibited breast cancer cell proliferation, disturbed cell cycle distribution and induced apoptosis in vitro. These findings suggested that ERCC6L, which is highly expressed in breast cancer, acts as an oncogene, is involved in breast cancer development and may serve as a novel molecular target for the treatment of breast cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It plays wide roles in regulating cell division, cell proliferation and other biological processes and is considered as a genetic marker in the development of tumours . It was reported that ERCC6L was relevant to disease progression and poor prognosis in many types of cancer, such as breast, renal and colorectal cancer . High expression of ERCC6L plus its role in embryonic development and the involvement of remodelling centromeric chromatin remind us to hypothesize that it may play a key role in tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of hub genes for lymph node metastasis in patients with prostate cancer

Chen

Lin

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

| INTRODUC TI ONProstate cancer (PCa) is the fifth principal cause of death and also the second most frequent cancer in males all over the world. 1 More than 15% of PCa patients harbour lymph node metastasis at radical prostatectomy. 2 Lymph node metastasis is a complicated process in which cancer cells leave the primary tumour site through the lymphatic system and then establish a secondary tumour site in lymph nodes. 3 These individuals have a higher risk of recurrence after primary treatment and usually suffer a poor prognosis. 4 Therefore, predicting the occurrence of lymph node metastasis is of vital clinical significance. At the present day, several nomograms and indexes AbstractLymph node metastasis is one of the most important independent risk factors that can negatively affect the prognosis of prostate cancer (PCa); however, the exact mechanisms have not been well studied. This study aims to better understand the underlying mechanism of lymph node metastasis in PCa by bioinformatics analysis.We analysed a total of 367 PCa cases from the cancer genome atlas database and performed weighted gene co-expression network analysis to explore some modules related to lymph node metastasis. Gene Ontology analysis and pathway enrichment analysis were conducted for functional annotation, and a protein-protein interaction network was built. Samples from the International Cancer Genomics Consortium database were used as a validation set. The turquoise module showed the most relevance with lymph node metastasis. Functional annotation showed that biological processes and pathways were mainly related to activation of the processes of cell cycle and mitosis. Four hub genes were selected: CKAP2L, CDCA8, ERCC6L and ARPC1A. Further validation showed that the four hub genes well-distinguished tumour and normal tissues, and they were good biomarkers for lymph node metastasis of PCa. In conclusion, the identified hub genes facilitate our knowledge of the underlying molecular mechanism for lymph node metastasis of PCa. K E Y W O R D Shub genes, lymph node metastasis, prostate cancer, weighted gene co-expression network analysis

show abstract

“…However, the expression of ERCC6L was significantly downregulated after birth and no expression of ERCC6L was detected in most adult organs. Previous studies have shown that ERCC6L is highly expressed in many types of human solid tumors and is therefore considered a potential target for tumor therapy, 40 but its exact role in CRC is unclear. In this study, the bioinformatics analysis of ERCC6L may play an important role in the occurrence and development of CRC.…”

Section: Discussionmentioning

confidence: 99%

Identification of potential hub genes via bioinformatics analysis combined with experimental verification in colorectal cancer

Zhou

Yang

Yue

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a kind of malignant cancer with high morbidity and mortality. The purpose of this study was to explore potential regulated key genes involved in CRC through bioinformatics analysis and experimental verification. The gene expression profile data were downloaded from the Gene Expression Omnibus, and the differential expression genes were detected in cancerous and paracancerous samples of CRC patients, respectively. Then functional enrichment analysis, such as the Kyoto Encyclopedia of Genes and Genomes pathway analysis as well as the protein‐protein interaction network were constructed, and the highly related genes were clustered by Molecular COmplex DEtection algorithm to find out the core interaction in different genes' crosstalk. The genes affecting CRC prognosis were screened by the Human Protein Atlas database. In addition, the expression level of core genes was detected by GEPIA database, and the core genes' changes in large‐scale cancer genome data set were directly analyzed by cBioPortal database. The expression of the predicted hub genes DSN1, AHCY, and ERCC6L was verified by reverse‐transcription quantitative polymerase chain reaction in CRC cells. The gene function of DSN1 was analyzed by wound healing and colony formation assays. The results showed that silencing of DSN1 could significantly reduce the migration and proliferation of CRC cells. Further, BUB1B, the potential interacting protein of DSN1, was also predicted via bioinformatics analysis. Above all, this study shows that bioinformatics analysis combined with experimental method verification provide more potential vital genes for the prevention and therapy of CRC.

show abstract

ERCC6L, a DNA helicase, is involved in cell proliferation and associated with survival and progress in breast and kidney cancers

Cited by 35 publications

References 28 publications

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

Development and validation of hub genes for lymph node metastasis in patients with prostate cancer

Identification of potential hub genes via bioinformatics analysis combined with experimental verification in colorectal cancer

Contact Info

Product

Resources

About